Tag Archives: IP

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, IP, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , | Leave a comment

Does IP Stimulate Growth and Create Jobs? New European Data Says Yes

A new study shows the importance of intellectual property in stimulating jobs and productivity in the EU. Surprisingly, it illustrates pharma’s established position as an IP powerhouse, evidence that adds conviction to the views expressed by GSK CEO Andrew Witty and other industry leaders that growing cuts on drug pricing are limiting an industry that […]
Posted in Europe, IP | Also tagged , , , , , , , | 1 Comment

Drug Patents Under Fire in Brazil

by Ryan O’Quinn & Sanya Sukduang One of the most promising pharmaceutical markets of the future is Brazil, a nation of nearly 200 million people with a universal healthcare system.  Brazil’s infamously overloaded patent system has undergone a series of recent reforms.  One such “reform,” however, greatly complicates biopharmaceutical patent practice: any Brazilian patent application […]
Posted in Regulatory | Also tagged , , , , , | 1 Comment

PhRMA Dismayed by Global IPR Report

Posted in Global, Guest Blog, IP, Regulatory | Also tagged , , | Leave a comment

Does India's Glivec Decision Make April Fools of Us All?

By Helen Disney, Pugatch Consilium. On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual […]
Posted in Global, Guest Blog, IP, Legal, Op-Ed | Also tagged , , | 2 Comments
  • Categories

  • Meta